The Effect of Postoperative Therapy on the Quality of Life of Patients With Early Cervical Cancer Research

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified November 2013 by Peking University
Sponsor:
Information provided by (Responsible Party):
Yunong Gao, Peking University
ClinicalTrials.gov Identifier:
NCT02018003
First received: December 17, 2013
Last updated: December 20, 2013
Last verified: November 2013
  Purpose

The purpose of this study is to assess the women's quality of life, who accepted chemotherapy,radiotherapy, concurrent radiochemotherapy or who didn't accept therapy, after operation.


Condition
Uterine Cervical Neoplasms

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Effect of Postoperative Therapy on the Quality of Life of Patients With Early Stage Cervical Cancer

Resource links provided by NLM:


Further study details as provided by Peking University:

Primary Outcome Measures:
  • Quality of life for the women with early stage cervical cancer who underwent operation [ Time Frame: up to 12 months after operation ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 180
Study Start Date: January 2014
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Detailed Description:

The study projects to follow up 180-200 early stage cervical cancer patients after operation and assess the women's quality of life by the scales: ECOG, Functional Assessment of Cancer Therapy, EuroQol-5 Dimensions, and Kupperman index.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

The women with early stage cervical cancer, who underwent operation in Peking University School of Oncology.

Criteria

Inclusion Criteria:

  • ≮ 18 years, cervical cancer verified by pathology,

    • IIA stage, accepted the operation ( Piver III and pelvic lymph node dissection) as initial therapy, obtained the patient's agreement

Exclusion Criteria:

  • the patient had accepted chemotherapy or radiotherapy before operation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02018003

Contacts
Contact: Gao Weijiao 86-10-88196102 gaoweijiao@126.com

Sponsors and Collaborators
Peking University
Investigators
Study Director: Gao Yunong Peking University
  More Information

No publications provided

Responsible Party: Yunong Gao, the head of department of gynecological oncology, Peking University
ClinicalTrials.gov Identifier: NCT02018003     History of Changes
Other Study ID Numbers: PUCRP201309
Study First Received: December 17, 2013
Last Updated: December 20, 2013
Health Authority: China: Ethics Committee

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female

ClinicalTrials.gov processed this record on September 18, 2014